Protagenic Therapeutics, Inc. (together with its subsidiary, Protagenic, the Company, we, our or us ) is a biopharmaceutical company focused on discovering and developing therapeutics for stress-related neuropsychiatric and mood disorders. Our proprietary, patent-protected, first-in-class lead compound, PT00114, is a synthetic form of Teneurin Carboxy-terminal Associated Peptide-1 ( TCAP-1 ).
Valuation & Multiples
Based on TTM earnings · Diluted shares
Profitability & Returns
Revenue (FY)
$0.00
Net Income (TTM)
$5M
▲ +138.1% YoY
Op. Margin
–
ROIC
-126.25%
▼ -13.2pp YoY
Cash Flow & Balance Sheet
FCF (TTM)
-$2M
▼ -58.9% YoY
Op. Cash Flow (TTM)
-$2M
▼ -58.7% YoY
Net Debt
-$566K
Net Cash Position
Cash & Equiv.
$566K
Continue Research
Peers
Pharmaceutical Preparations · Pick stocks to compare with PTIX
Protagenic Therapeutics (PTIX) in three numbers
Questions about Protagenic Therapeutics
Is Protagenic Therapeutics (PTIX) overvalued?
Protagenic Therapeutics trades at 0.45 times earnings. Intrinsiqq's fair value calculator has no opening value for PTIX, so weigh those multiples against the company's own history and the peers above. See how to tell if a stock is overvalued.
Is Protagenic Therapeutics a high-quality business?
Protagenic Therapeutics scores 20 out of 100 on Intrinsiqq's quality score, which makes it a lower-quality business on these measures. The score blends 5 checks computed from SEC filings. Its best check is net debt at -$565985, and its weakest is return on capital at -126.2%. The Quality tab shows every check against its target.
Does Protagenic Therapeutics (PTIX) pay a dividend?
No. Protagenic Therapeutics (PTIX) does not pay a dividend, and no dividend payment appears anywhere in the filing history we hold. Nor has its share count fallen meaningfully over the last twelve months, so cash is kept in the business. The Dividends tab shows its cash returns.
Source: 10-Q filed 19 Aug 2026 (period ending 30 Jun 2026), SEC. Price: last close 3 Nov 2026. How this is calculated. Sector medians are approximate S&P 500 benchmarks and update periodically. Analysis, not investment advice.
Spot a number that looks wrong? Check it in PTIX's SEC filings or
Download this analysis as a PDF (Pro)
Data sourced from SEC EDGAR filings and third-party price providers. Scores, valuations, and metrics are algorithmic estimates. This is not investment advice. See our Terms and Methodology.
Keep analysing PTIX
Create a free account and get 14 days of Premium: every stock and every tool.
- Unlimited stocks
- Stock screener
- Portfolio tracker
- Editable DCF
- Compare side by side
- Unlimited alerts
No card. Moves to Free after, unless you upgrade.
Already have an account?
Or come back tomorrow. Stocks on your watchlist are always free to view.